Literature DB >> 23560485

Roles of histone methyl-modifying enzymes in development and progression of cancer.

Takeshi Suzuki1, Minoru Terashima, Shoichiro Tange, Akihiko Ishimura.   

Abstract

Retroviral insertional mutagenesis in mice is considered a powerful forward genetic strategy to identify disease genes involved in cancer. Our high-throughput screens led to frequent identification of the genes encoding the enzymes engaged in histone lysine methylation. Histone methylation can positively or negatively impact on gene transcription, and then fulfill important roles in developmental control and cell-fate decisions. A tremendous amount of progress has accelerated the characterization of histone methylations and the enzymes that regulate them. Deregulation of these histone methyl-modifying enzymes has been increasingly recognized as a hallmark of cancer in the last few years. However, in most cases, we have only limited understanding for the molecular mechanisms by which these enzymes contribute to cancer development and progression. In this review, we summarize the current knowledge regarding some of the best-validated examples of histone lysine methyltransferases and demethylases associated with oncogenesis and discuss their potential mechanisms of action.
© 2013 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23560485     DOI: 10.1111/cas.12169

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  12 in total

1.  Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas.

Authors:  Edward A Ratovitski
Journal:  Cell Cycle       Date:  2014-01-06       Impact factor: 4.534

2.  MEG8 long noncoding RNA contributes to epigenetic progression of the epithelial-mesenchymal transition of lung and pancreatic cancer cells.

Authors:  Minoru Terashima; Akihiko Ishimura; Sasithorn Wanna-Udom; Takeshi Suzuki
Journal:  J Biol Chem       Date:  2018-09-27       Impact factor: 5.157

3.  MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines.

Authors:  Minoru Terashima; Shoichiro Tange; Akihiko Ishimura; Takeshi Suzuki
Journal:  J Biol Chem       Date:  2016-11-16       Impact factor: 5.157

4.  SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.

Authors:  Filipa Quintela Vieira; Pedro Costa-Pinheiro; Diogo Almeida-Rios; Inês Graça; Sara Monteiro-Reis; Susana Simões-Sousa; Isa Carneiro; Elsa Joana Sousa; Maria Inês Godinho; Fátima Baltazar; Rui Henrique; Carmen Jerónimo
Journal:  Oncotarget       Date:  2015-05-30

5.  JARID2 is involved in transforming growth factor-beta-induced epithelial-mesenchymal transition of lung and colon cancer cell lines.

Authors:  Shoichiro Tange; Dulamsuren Oktyabri; Minoru Terashima; Akihiko Ishimura; Takeshi Suzuki
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

Review 6.  DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.

Authors:  Omar Castillo-Aguilera; Patrick Depreux; Ludovic Halby; Paola B Arimondo; Laurence Goossens
Journal:  Biomolecules       Date:  2017-01-05

7.  JMJD-1.2 controls multiple histone post-translational modifications in germ cells and protects the genome from replication stress.

Authors:  Toshia R Myers; Pier Giorgio Amendola; Yvonne C Lussi; Anna Elisabetta Salcini
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

8.  Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: prognostic and therapeutic implications.

Authors:  Aman Kumar; Niti Kumari; Ujjawal Sharma; Sant Ram; Shrawan Kumar Singh; Nandita Kakkar; Karanvir Kaushal; Rajendra Prasad
Journal:  Sci Rep       Date:  2019-06-03       Impact factor: 4.379

Review 9.  Lysine methylation of transcription factors in cancer.

Authors:  Dong Han; Mengxi Huang; Ting Wang; Zhiping Li; Yanyan Chen; Chao Liu; Zengjie Lei; Xiaoyuan Chu
Journal:  Cell Death Dis       Date:  2019-03-29       Impact factor: 8.469

10.  HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia.

Authors:  Aida Vitkevičienė; Giedrė Skiauterytė; Andrius Žučenka; Mindaugas Stoškus; Eglė Gineikienė; Veronika Borutinskaitė; Laimonas Griškevičius; Rūta Navakauskienė
Journal:  J Oncol       Date:  2019-07-18       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.